AAV-DJ–Mediated MYOC Silencing as a Gene Therapy Approach for Myocilin-Associated Glaucoma

Yue Wan; Xiangxiang Liu; Xuejing Yan; Shen Wu; Yufei Teng; Luyi Han; Jiaxiang Zhang; Ningli Wang

doi:10.1167/iovs.67.1.48

January 22, 2026Investigative Ophthalmology & Visual ScienceOpen Access

AAV-DJ–Mediated MYOC Silencing as a Gene Therapy Approach for Myocilin-Associated Glaucoma

View Full Paper

Ask AI

Bookmark

Share

Key Points

To investigate the effectiveness of AAV-DJ-mediated MYOC silencing in treating myocilin-associated glaucoma.
Used Tg-MYOCP370L mice as a model for myocilin-associated glaucoma.
Administered AAV-DJ for MYOC silencing.
Evaluated glaucomatous pathology
Gene therapy significantly reduced glaucomatous symptoms in the mice.
Observed improvements in eye health and function.

Implication

This research demonstrates MYOC silencing improves glaucoma in mice, indicating a promising gene therapy method.

Abstract

AAV-DJ-mediated MYOC silencing effectively alleviated glaucomatous pathology in Tg-MYOCP370L mice, highlighting its potential as a gene therapy strategy for myocilin-associated glaucoma.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wan et al. (2026) studied this question.

synapsesocial.com/papers/697461a8bb9d90c67120b8af https://doi.org/10.1167/iovs.67.1.48

View Full Paper

Ask AI

Bookmark

Share

AAV-DJ–Mediated MYOC Silencing as a Gene Therapy Approach for Myocilin-Associated Glaucoma

Key Points

Implication

Abstract

Discussion

Cite This Study

AAV-DJ–Mediated MYOC Silencing as a Gene Therapy Approach for Myocilin-Associated Glaucoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading